X0306 4 2020-10-10 1 0001631650 Aimmune Therapeutics, Inc. AIMT 0001415537 Iwicki Mark T C/O AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 1 0 0 0 Common Stock, $0.0001 par value 2020-10-10 4 U 0 39567 34.50 D 0 D Common Stock, $0.0001 par value 2020-10-13 4 D 0 7840 34.50 D 0 D Stock Option (right to buy) 3.02 2020-10-13 4 D 0 52421 31.48 D Common Stock 52421 0 D Stock Option (right to buy) 6.29 2020-10-13 4 D 0 87368 28.21 D Common Stock 87368 0 D Stock Option (right to buy) 15.40 2020-10-13 4 D 0 19755 19.10 D Common Stock 19755 0 D Stock Option (right to buy) 18.26 2020-10-13 4 D 0 17500 16.24 D Common Stock 17500 0 D Stock Option (right to buy) 32.79 2020-10-13 4 D 0 7500 1.71 D Common Stock 7500 0 D Stock Option (right to buy) 19.90 2020-10-13 4 D 0 11432 14.60 D Common Stock 11432 0 D Stock Option (right to buy) 17.11 2020-10-13 4 D 0 15398 17.39 D Common Stock 15398 0 D Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. /s/ Douglas T. Sheehy, as Attorney-in-Fact for Mark T. Iwicki 2020-10-14